Is DIAGNOS Inc. (DGNOF) a Buy, Sell, or Hold?
OTC : DGNOF
DIAGNOS Inc.
$0.16 USD
-$0.01 (-5.88%)
- Volume
- 62.5K
- Average Volume
- 95.1K
- Market Capitalization
- $16.3M
- P/E Ratio
- -5.81
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.29
- Year Low
- $0.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.49
Company Overview
OTC
Andre Larente
Medical - Healthcare Information Services
Healthcare
DGNOF
22
CA
USD
Liquidity Metrics
2.04
1.49
1.49
0.21
0.00
Sales & Valuation
$65646
373.36
42.07
-6.32
-0.03
Profitability
-$0.0423
-$4.57M
-6956.84%
-6956.84%
11659.44%
-190.55%
P/E Metrics
-5.81
-0.42
-0.42
Analyst Price Target & Rating
1/5
0 Analysts
%
Financial Health Scores
-31.94
3/9
$724.1K
$2.4M
$1.71M
-$4.19M
Key Metrics (TTM)
$25.54M
390.04
-6.24
1.49
11659.44%
-204.11%
-15.76%
-15.81%
763 days
Company Executives
| Name | Title |
|---|---|
| Andre Larente | Chief Executive Officer, President & Executive Director |
| Marc-André Massue | Vice President of Finance, Chief Financial Officer & Secretary |
| Yves-Stéphane Couture | Chief Operating Officer |
| Ismail Ben Ayed | Chief Artificial Intelligence Scientist |
Poll Results
No votes yet today — be the first to share your view!
About DIAGNOS Inc. (OTC:DGNOF) Stock
DIAGNOS Inc. specializes in delivering technology-driven services, with its reach primarily extending across Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A cornerstone of its offerings is Computer Assisted Retina Analysis (CARA), a web-based software application in the healthcare sector. This innovative tool is designed to aid medical professionals in identifying diabetic retinopathy, empowering eye care specialists to clearly visualize both normal anatomical features of the retina and any disease-related changes. Beyond its medical applications, the company also furnishes expert consulting services in the domains of data analytics and artificial intelligence. Established in 1998, DIAGNOS maintains its principal office in Brossard, Canada. ...
DIAGNOS to Extend the Exercise Period of Stock Warrants
2026-07-07 12:38:52
BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a "Warrant") from August 5, 2026 to June 5, 2027 (the "Amendment").
2026-06-05 10:00:00
BROSSARD, Quebec, June 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that Emerging Growth Research today released a new flash report on DIAGNOS, highlighting the Company's progress toward key regulatory approvals and the growing commercialization opportunity for its CARA (Computer Assisted Retinal Analysis) artificial intelligence platform.
DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026
2026-06-03 10:00:00
DIAGNOS invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. BROSSARD, Quebec, June 03, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that Mr.
DIAGNOS Announces Amendment to Convertible Debentures
2026-05-13 19:00:00
BROSSARD, Quebec, May 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to extend the maturity date of an aggregate amount of $300,000 of unsecured convertible debentures (each, a Debenture) issued as part of a non-brokered private placement of units initially announced on May 18, 2023, and subsequently amended on May 18, 2025 (pleaser refer to the press release dated May 20, 2025). The amended maturity date set for May 18, 2026, is extended to May 18, 2027 (the “Amendment”).
Frequently Asked Questions
-
What is the current DIAGNOS Inc. (DGNOF) stock price?
-
DIAGNOS Inc.(OTC:DGNOF) stock price is $0.16 in the last trading session. During the trading session, DGNOF stock reached the peak price of $0.29 while $0.13 was the lowest point it dropped to. The percentage change in DGNOF stock occurred in the recent session was --5.88% while the dollar amount for the price change in DGNOF stock was -$0.01.
-
DGNOF's industry and sector of operation?
-
The OTC listed DGNOF is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector.
-
Who are the executives of DGNOF?
-
Andre Larente | Chief Executive Officer, President & Executive Director
Marc-André Massue | Vice President of Finance, Chief Financial Officer & Secretary
Yves-Stéphane Couture | Chief Operating Officer
Ismail Ben Ayed | Chief Artificial Intelligence Scientist
| -
How many employees does DGNOF have?
-
Number of DGNOF employees currently stands at 22. DGNOF operates from 7005 Taschereau Boulevard, Brossard, QC J4Z 1A7, CA.
-
Link for DGNOF official website?
-
Official Website of DGNOF is: https://www.diagnos.ca
-
How do I contact DGNOF?
-
DGNOF could be contacted at phone #450 678 8882 and can also be accessed through its website. DGNOF operates from 7005 Taschereau Boulevard, Brossard, QC J4Z 1A7, CA.
-
How many shares of DGNOF are traded daily?
-
The average number of DGNOF shares traded daily for last 3 months was 95.1K.
-
What is the market cap of DGNOF currently?
-
The market value of DGNOF currently stands at $16.3M with its latest stock price at $0.16